Signs of Promise for HCV Vaccine, But Enough?

The first study of its kind has concluded that although a novel vaccine against hepatitis C does not seem to ...

MAY 11, 2020

Short-Course Treatment Opens Door to HCV+ Organ Transplants

Boston—Combination therapy with direct-acting antivirals (DAAs) and the cholesterol drug ezetimibe is ...

FEBRUARY 10, 2020

Linkage to Care Key to Address Evolving Hep C Epidemic

People who inject drugs and subsequently contract the hepatitis C virus may be overlooked by the health care ...

OCTOBER 10, 2019

Large Study Confirms DAAs Protect Against HCC When SVR Achieved

Patients with hepatitis C who are successfully treated with direct-acting antiviral agents experience a dramatic ...

FEBRUARY 23, 2018

Fibrosis Regression Slower Than Thought for HCV Patients on DAAs

New findings confirm that regression of liver fibrosis after sustained virologic response is possible after ...

NOVEMBER 3, 2017

ISMP Report Links Hep C Drugs to Liver Failure

The Institute for Safe Medication Practices has released a report warning that severe side effects, including liver ...

FEBRUARY 22, 2017

The FDA Approves Zepatier To Treat HCV 

Zepatier achieves SVR12 in a broad range of HCV patients, including those with compensated cirrhosis, renal ...

JANUARY 29, 2016